
April 10, 2024
Occasionally, hospice clinicians may encounter patients with enteral feeding tubes (FTs). These tubes are used to provide enteral nutrition (EN) in individuals with a functioning GI tract who are otherwise unable to be fed orally.1 There are numerous types of tubes out there which are generally classified by insertion site and where in the body they end up.1-3 Also, tube type will vary by intended duration of use.1-3
Since enteral tubes provide access to the GI tract, they can sometimes be used to administer medications in those unable to take them orally.1 Although not all drugs are appropriate for tube administration, such as ER tablets or drugs that act locally / are absorbed at sites prior to the tube’s endpoint. Table 1 lists some drugs whose absorption / effects could be compromised depending on where the tube ends.
Generally, gastric tubes are preferred for drug administration since they’re larger (less likely to clog) and some medications are better tolerated in the stomach.1 Also, liquid preparations are usually first-line since they’re less likely to occlude a tube and are readily absorbed.1 One notable exception is ciprofloxacin suspension, because its oil-based formulation adheres to feeding tubes. Of the different types of liquids available, suspensions or elixirs are preferred over syrups because they’re less likely to cause clumping if exposed to EN.1 Notably, liquid drug formulations tend to be less concentrated (they’re usually intended for children) and the larger volumes needed for adult doses can contribute to intolerance.
Medications and some EN products may be hyperosmolar, meaning they have a higher concentration of particles dissolved in them relative to a human cell, so water gets drawn out of the cells in the intestine, which could lead to cramping and diarrhea. Specifically, sorbitol is a sweetening agent that can have an osmotic laxative effect.1,2,4 Since patients might be taking multiple sorbitol-containing liquid formulations it’s important to be aware of their cumulative effects – the osmotic laxative effect is typically seen with sorbitol doses of 20g/day and up, but doses as low as 10g/day have been linked to bloating and flatulence.1
When a liquid preparation isn’t an option, crushing immediate release tablets or opening capsules may be considered. Be sure to consult your organization’s do not crush list, the OPPC Clinical Symptom Guide, or your pharmacist to make sure the medication in question can be crushed / opened and is compatible with enteral tube administration. Some best practices for giving drugs via enteral tubes are described in Table 2.
Feeding tube blockage is a significant complication that occurs in up to 35% of patients.3 This can occur due to mechanical failure, kinked tubing, feed precipitation, stagnant feeds, contamination, cyclical feeding, inappropriate medication administration, and/or inadequate flushing1-3 Maintaining tube patency is largely dependent on following best practices, especially regular flushing.3 A number of solutions (e.g., colas, juices, meat tenderizer) have been proposed as flushing agents, but nothing has been shown to be superior to water in preventing a blockage.3
If tubes should become blocked, there are a few interventions to consider: liquid irrigants (water), pancreatic enzymes, Clog Zapper and mechanical devices (Table 3).1-3 Liquid irrigation with water and a syringe is first-line, but is often a time consuming process that requires patience.2,3 Pancreatic enzymes (and likely Clog Zapper) appear to only be useful for clogs caused by EN and are unlikely to provide benefit for those caused by medications.3 Notably, pancreatic enzymes need to be given with sodium bicarbonate to raise pH sufficiently to “activate” the enzyme.3 Finally, mechanical devices are typically meant for specific tubes and require special training.2
While most hospice patients won’t have enteral tubes as a potential route for drug administration, clinicians should be familiar with them as there are a number of considerations to ensure safe and effective medication use.
Written by: OnePoint Patient Care Clinical Team
Joseph Solien, PharmD, BCGP, BCPP – Vice President of Clinical Services
Melissa Corak, PharmD, BCGP – Senior Clinical Pharmacist
John Corrigan, PharmD, BCGP – Clinical Pharmacist
References